Becton, Dickinson and Company Peer Comparison
| Metric | Value | Ranking | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $66.6 Billion | 1/11 | BDX $66.6B |
RMD $32.5B |
WST $16.4B |
COO $16.1B |
HOLX $13.7B |
RGEN $8.1B |
TFX $6.5B |
ICUI $3.6B |
HAE $3.2B |
XRAY $3.1B |
ANGO $399.4M |
| Gross Margin | 43% | 9/11 | COO 67% |
RMD 59% |
HOLX 57% |
HAE 56% |
TFX 55% |
ANGO 55% |
RGEN 50% |
XRAY 49% |
BDX 43% |
WST 37% |
ICUI 36% |
| Profit Margin | 6% | 6/11 | RMD 27% |
HOLX 20% |
WST 17% |
COO 12% |
HAE 11% |
BDX 6% |
ICUI -4% |
ANGO -15% |
TFX -17% |
RGEN -20% |
XRAY -48% |
| EBITDA margin | 9% | 8/11 | HOLX 34% |
RMD 28% |
WST 27% |
RGEN 20% |
COO 19% |
HAE 17% |
ICUI 14% |
BDX 9% |
ANGO -3% |
TFX -5% |
XRAY -56% |
| Quarterly Revenue | $5.2 Billion | 1/11 | BDX $5.2B |
RMD $1.3B |
HOLX $1.0B |
COO $1.0B |
XRAY $905.0M |
TFX $795.4M |
WST $748.8M |
ICUI $629.8M |
HAE $348.5M |
RGEN $167.5M |
ANGO $72.8M |
| Quarterly Earnings | $303.0 Million | 2/11 | RMD $344.6M |
BDX $303.0M |
HOLX $201.0M |
WST $130.1M |
COO $117.5M |
HAE $37.5M |
ANGO -$10.7M |
ICUI -$23.8M |
RGEN -$33.9M |
TFX -$136.7M |
XRAY -$430.0M |
| Quarterly Free Cash Flow | $588.0 Million | 1/11 | BDX $588.0M |
RMD $289.7M |
HOLX $172.5M |
TFX $170.4M |
WST $85.2M |
HAE $35.2M |
ICUI $13.6M |
ANGO $1.7M |
XRAY -$0 |
COO -$0 |
RGEN -$0 |
| Trailing 4 Quarters Revenue | $20.6 Billion | 1/11 | BDX $20.6B |
RMD $4.9B |
HOLX $4.0B |
XRAY $3.8B |
TFX $3.0B |
COO $3.0B |
WST $2.9B |
ICUI $2.4B |
HAE $1.4B |
RGEN $614.2M |
ANGO $286.5M |
| Trailing 4 Quarters Earnings | $1.7 Billion | 1/11 | BDX $5.2B |
RMD $1.3B |
HOLX $1.0B |
COO $1.0B |
XRAY $905.0M |
TFX $795.4M |
WST $748.8M |
ICUI $629.8M |
HAE $348.5M |
RGEN $167.5M |
ANGO $72.8M |
| Quarterly Earnings Growth | 8% | 5/11 | RMD 65% |
ANGO 63% |
COO 39% |
HAE 20% |
BDX 8% |
XRAY 0% |
WST -5% |
HOLX -18% |
RGEN -33% |
ICUI -39% |
TFX -539% |
| Annual Earnings Growth | 135% | 1/11 | BDX 135% |
HOLX 44% |
RMD 44% |
HAE 23% |
COO 15% |
XRAY -14% |
WST -21% |
TFX -84% |
RGEN -135% |
ANGO -307% |
ICUI -2677% |
| Quarterly Revenue Growth | 10% | 3/11 | XRAY 5556% |
HOLX 268% |
BDX 10% |
RMD 10% |
COO 10% |
RGEN 8% |
ICUI 7% |
HAE 4% |
TFX 3% |
WST 2% |
ANGO -8% |
| Annual Revenue Growth | 3% | 7/11 | XRAY 33% |
HOLX 30% |
RMD 22% |
HAE 6% |
ICUI 6% |
RGEN 6% |
BDX 3% |
TFX 1% |
WST -3% |
ANGO -9% |
COO -20% |
| Cash On Hand | $711.0 Million | 2/11 | HOLX $1.8B |
BDX $711.0M |
RMD $521.9M |
WST $484.6M |
HAE $320.8M |
ICUI $308.6M |
TFX $290.2M |
XRAY $272.0M |
COO $107.6M |
ANGO $54.1M |
RGEN -$0 |
| Short Term Debt | $1.3 Billion | 1/11 | BDX $1.3B |
XRAY $549.0M |
TFX $100.0M |
HOLX $53.4M |
ICUI $51.0M |
RMD $37.7M |
COO $33.3M |
WST $17.9M |
HAE $5.1M |
ANGO -$0 |
RGEN -$0 |
| Long Term Debt | $17.4 Billion | 1/11 | BDX $17.4B |
COO $2.6B |
XRAY $1.7B |
TFX $1.7B |
ICUI $1.5B |
HAE $1.2B |
RMD $802.0M |
WST $284.4M |
HOLX $22.2M |
ANGO $0 |
RGEN $0 |
| PE | 38.08 | 3/11 | TFX 92.79 |
COO 40.98 |
BDX 38.08 |
WST 33.39 |
RMD 26.01 |
HAE 24.81 |
HOLX 18.40 |
XRAY -1.00 |
ANGO -1.00 |
ICUI -1.00 |
RGEN -1.00 |
| PS | 3.23 | 6/11 | RGEN 13.22 |
RMD 6.59 |
WST 5.69 |
COO 5.42 |
HOLX 3.39 |
BDX 3.23 |
HAE 2.35 |
TFX 2.12 |
ICUI 1.53 |
ANGO 1.39 |
XRAY 0.82 |
| PB | 2.64 | 6/11 | RMD 6.18 |
WST 6.13 |
RGEN 4.02 |
HAE 3.56 |
HOLX 2.87 |
BDX 2.64 |
ANGO 2.14 |
COO 1.99 |
ICUI 1.85 |
XRAY 1.60 |
TFX 1.51 |
| PC | 93.63 | 2/11 | COO 149.41 |
BDX 93.63 |
RMD 62.22 |
WST 33.95 |
TFX 22.28 |
ICUI 11.77 |
XRAY 11.46 |
HAE 10.06 |
HOLX 7.68 |
ANGO 7.38 |
RGEN -1.00 |
| Liabilities to Equity | 1.17 | 3/11 | XRAY 1.96 |
HAE 1.79 |
BDX 1.17 |
ICUI 1.14 |
HOLX 0.83 |
TFX 0.66 |
ANGO 0.56 |
COO 0.52 |
RMD 0.36 |
WST 0.36 |
RGEN -1.00 |
| ROA | 0.03 | 5/11 | RMD 17% | WST 14% | HOLX 9% | HAE 5% | BDX 3% | COO 3% | TFX 1% | ICUI -3% | XRAY -16% | ANGO -77% | RGEN -100% |
| ROE | 0.07 | 5/11 | RMD 24% |
WST 18% |
HOLX 16% |
HAE 14% |
BDX 7% |
COO 5% |
TFX 2% |
RGEN -1% |
ICUI -6% |
XRAY -47% |
ANGO -120% |
| Current Ratio | 1.86 | 8/11 | WST 3.79 |
RMD 3.78 |
COO 2.91 |
ANGO 2.78 |
TFX 2.52 |
HOLX 2.21 |
ICUI 1.88 |
BDX 1.86 |
HAE 1.56 |
XRAY 1.51 |
RGEN 0.00 |
| Quick Ratio | 0.02 | 10/11 | TFX 92.79 |
COO 40.98 |
BDX 38.08 |
WST 33.39 |
RMD 26.01 |
HAE 24.81 |
HOLX 18.40 |
XRAY -1.00 |
ANGO -1.00 |
ICUI -1.00 |
RGEN -1.00 |
| Long Term Debt to Equity | 0.69 | 4/11 | HAE} 1.35 |
XRAY} 0.86 |
ICUI} 0.78 |
BDX} 0.69 |
TFX} 0.39 |
COO} 0.32 |
RMD} 0.15 |
WST} 0.11 |
HOLX} 0.00 |
ANGO} 0.00 |
RGEN} 0.00 |
| Debt to Equity | 0.74 | 4/11 | HAE 1.35 |
XRAY 1.15 |
ICUI 0.81 |
BDX 0.74 |
TFX 0.41 |
COO 0.32 |
RMD 0.16 |
WST 0.11 |
HOLX 0.01 |
ANGO 0.00 |
RGEN 0.00 |
| Burn Rate | 0.98 | 5/11 | HAE 25.53 |
ANGO 5.04 |
ICUI 3.15 |
TFX 1.27 |
BDX 0.98 |
XRAY 0.43 |
RGEN 0.00 |
RMD -1.72 |
WST -4.24 |
HOLX -9.54 |
COO -15.03 |
| Cash to Cap | 0.01 | 9/11 | ANGO 0.14 |
HOLX 0.13 |
HAE 0.10 |
XRAY 0.09 |
ICUI 0.08 |
TFX 0.04 |
WST 0.03 |
RMD 0.02 |
BDX 0.01 |
COO 0.01 |
RGEN 0.00 |
| CCR | 1.94 | 1/11 | BDX 1.94 |
HAE 0.94 |
HOLX 0.86 |
RMD 0.84 |
WST 0.65 |
RGEN 0.00 |
ANGO -0.16 |
ICUI -0.57 |
TFX -1.25 |
XRAY |
COO |
| EV to EBITDA | 186.80 | 2/11 | RGEN} 240.77 |
BDX} 186.80 |
COO} 93.51 |
RMD} 90.54 |
WST} 79.43 |
HAE} 69.99 |
ICUI} 56.11 |
HOLX} 33.96 |
XRAY} -9.96 |
ANGO} -137.68 |
TFX} -218.25 |
| EV to Revenue | 4.10 | 5/11 | RGEN 13.22 |
RMD 6.66 |
COO 6.26 |
WST 5.62 |
BDX 4.10 |
HAE 3.01 |
HOLX 2.96 |
TFX 2.60 |
ICUI 2.06 |
XRAY 1.34 |
ANGO 1.21 |